The essential splicing factor ASF/SF2 activates or represses splicing depending on where on the pre-mRNA it binds. We have previously shown that ASF/SF2 inhibits adenovirus IIIa pre-mRNA splicing by binding to an intronic repressor element. Here we used MS2-ASF/SF2 fusion proteins to show that the second RNA binding domain (RBD2) is both necessary and sufficient for the splicing repressor function of ASF/SF2. Further, we show that the completely conserved SWQDLKD motif in ASF/SF2-RBD2 is essential for splicing repression.
Introduction
mRNA in a total volume 25 µl. The final MgCl 2 concentration varied between 2.5-3.5 mM, depending on the substrate [3.2 mM for IIIa-MS2I and IIIa-MS2I(inv) transcripts; 3.5 mM for glob-MS2I transcript; 2.5 mM for IIIa-MS2E
and IIIa-MS2E(inv) transcripts]. The indicated amounts (see figure legends) of MS2 hybrid proteins were preincubated for 10 min at 30°C with the pre-mRNA in a reaction mixture containing all components except the nuclear extract. Splicing was initiated by addition of HeLa-NE and reaction mixtures incubated at 30°C for 1-3 h. Reaction products were resolved on denaturing 8% polyacrylamide denaturing gels and visualized by autoradiography. The identity of spliced products and intermediates were assigned based on size. Dried gels were subjected to PhosphorImager quantification as previously described (23).
Quantitative data given in the text were based on three, or more, independent experiments.
Mobility shift assay
Short 32 P-labeled RNA transcripts containing the MS2 operator site in a direct or inverted orientation were generated by T7 transcription (28). Binding conditions and gel analysis was essentially as previously described (24). Briefly, 15 fmol 
RESULTS

An MS2-ASF/SF2 fusion protein inhibits IIIa splicing
We previously showed that the ASF/SF2∆RS protein efficiently represses IIIa splicing (20) . The aim of this study was to determine whether a specific sequence element within the RBDs was necessary for the splicing repressor phenotype of ASF/SF2. However, mutating the ASF/SF2-RBDs would be expected to impair the RNA binding capacity of the ASF/SF2 mutant proteins. We therefore reconstructed the ASF/SF2 deletion mutants as fusion proteins with the MS2 coat protein (Fig. 1A) , which binds to a well defined RNA steam loop structure, the MS2 operator (32).
However, replacing the 3RE in the IIIa pre-mRNA with an MS2 operator site positioned fifteen nucleotides upstream of the IIIa branch site (IIIa-MS2(-15); We therefore constructed a control transcript in which the 3RE was moved from its natural position at -6 relative to the IIIa branch site to position -53 (IIIa-3RE(-53); Fig. 2A ). As shown in Fig. 2C , addition of purified HeLa SR proteins efficiently repressed IIIa-3RE(-53) splicing (lanes 1-4). This inhibition was specific since SR proteins did not inhibit splicing of the IIIa-MS2I transcript (lanes [5] [6] [7] [8] , here used as a control. We conclude that the 3RE , also at a distance from the branch site, functions as a splicing repressor element (see also Discussion).
MS2-ASF/SF2 hybrid proteins were expressed and purified from E. coli as 6-His tagged proteins together with SR protein kinase 1 (SRPK1), as previously described (29). As shown in Fig. 3A , coexpression with SRPK1 was necessary for the MS2-ASF/SF2 protein to function as a splicing repressor protein. Thus, addition of increasing amounts of an unphosphorylated MS2-ASF/SF2 protein did not inhibit IIIa-MS2I splicing (Fig. 3A, lanes 1-5) . In contrast, addition of the same molar amount of an MS2-ASF/SF2 protein purified from SRPK1 coexpressing cells, resulted in a more than 5-fold repression of IIIa splicing (Fig.   3A , lanes 6-10). Unexpectedly, SRPK1 coexpression resulted in an increase in the RNA binding capacity of the MS2 fusion proteins (data not shown). Thus, the lack of activity of the unphosphorylated MS2-ASF/SF2 fusion protein appears to result from a failure to bind efficiently to the MS2 operator. Although SRPK1 is not expected to phosphorylate all MS2-ASF/SF2 hybrid proteins used in this study (Fig. 1A) we choose to purify all hybrid proteins from SRPK1 coexpressing cells. Fig. 1B shows a Coomassie stained gel of typical batches of MS2-ASF/SF2 hybrid proteins used in the experiments presented here.
As shown in Fig. 4 , the inhibitory effect of MS2-ASF/SF2 requires an MS2 operator site. Thus, using a IIIa-MS2I transcript with an inverted MS2 operator site IIIa-MS2I(inv) completely annulled the inhibitory effect of MS2-ASF/SF2 on IIIa splicing (Fig. 4, lanes 9-12) . This loss of splicing inhibition results from the fact that the MS2-ASF/SF2 protein does not bind to the inverted MS2 operator site (Fig. 3B, lane 9) . Fig. 3B further shows that all tested MS2-ASF/SF2 hybrid proteins bind efficiently (lanes [1] [2] [3] [4] [5] [6] [7] [8] and specifically (lanes 9-15) to the MS2 operator site. The appearance of multiple complexes most likely reflects the capacity of the MS2 protein to multimerize (see 33). It is interesting to note that the complexes formed were not retarded in migration, as one would have predicted from the relative size of the MS2 fusion proteins (Fig. 1B) , a result suggesting conformational variations.
MS2-ASF/SF2 does not inhibit IIIa splicing by steric interference
We have previously shown that ASF/SF2 inhibits IIIa splicing by preventing U2 snRNP recruitment to the IIIa branch site (20, 23). Since the ASF/SF2∆RS
protein also inhibited IIIa splicing we determined whether ASF/SF2 inhibition of splicing resulted from a steric interference. As shown in To further characterize the sequences in ASF/SF2-RBD2 required for splicing repression we constructed four mutants of MS2-RBD2+RS (Fig. 6A) . We choose MS2-RBD2+RS as the parental protein for mutant construction since this fusion protein was more robust, retaining the splicing regulatory activity better than MS2-RBD2; i.e. after multiple thawings or storage. The ASF/SF2 pre-mRNA is alternative spliced in vivo, generating three protein isoforms, which differ at their C-terminus (36). Two of the proteins lack the RS domain and approximately 12 amino acid residues from the carboxy-terminus of RBD2: amino acids corresponding to the β4 strand of RBD2 (Fig. 6A) . Removal of these residues inactivates ASF/SF2 as a constitutive splicing factor and regulator of alternative splicing (13) . As shown in Fig. 6B , deletion of the β4 strand abolished the inhibitory effect of MS2-RBD2+RS on IIIa-MS2I splicing. This result argues that the carboxy-terminus of RBD2 is required for the repressor function of ASF/SF2. Interestingly, the SWQDLKD motif contained in α-helix 1 is completely conserved in the RBD2 in all SR proteins containing two RBDs (see 37). In the predicted structure of ASF/SF2-RBD2 this helix is positioned opposite to the β 1 and β 3 strands making contact with the RNA. As shown in Fig. 8, lanes 5-8) . In contrast, tethering the MS2-ASF/SF2-RBD2 protein to the second exon had essentially no effect on IIIa-MS2E splicing (Fig. 8, lanes 1-4) . Interestingly, the MS2-RBD2+RS protein activated IIIa-MS2E splicing slightly better (approximately 4-fold) compared to the MS2-RS protein, suggesting that the RS domain may be the minimal domain required for the ASF/SF2 splicing enhancer function, but that RBD2 augments the enhancer activity of the RS domain.
Taken together, our results suggest that the activity of the RBD2 and the RS domains on splicing is opposite and position dependent.
DISCUSSION
Here we present evidence suggesting that the splicing enhancer and splicing repressor functions of ASF/SF2 can be separated and attributed to distinct (Fig. 8) . Furthermore, we show that the effects of the RS and RBD2 domains in splicing are position dependent and opposite. Thus, RBD2 inhibits splicing when tethered to the IIIa or the ß-globin introns ( Fig. 5 and 7 ), but has no negative effects when bound to the IIIa second exon (Fig. 8) . Conversely, the ASF/SF2-RS domain activates splicing slightly when tethered to the IIIa second exon (Fig. 8) , but has no effect when bound to the intron (Fig. 5) . (Fig. 4) . Second, protein binding to the so-called anchoring sequence (40) may preclude U2 snRNP recruitment to the branch site.
The anchoring sequence is the RNA sequence located immediately upstream of the branch site which make contact with the SF3 component of U2 snRNP (40) .
In the wild type IIIa transcript, the anchoring sequence is contained within the 3RE, likely contributing to the inhibitory effect of the 3RE on IIIa splicing. Such a conclusion is supported by our finding that positioning the highly structured MS2 operator site 15 nucleotides upstream of the IIIa branch site completely ablates IIIa splicing in the absence of any MS2 proteins (Fig. 2B ). This finding is compatible with the previous study (40) , which suggested that the single- whereas MS2-ASF/SF2 hybrid proteins lacking RBD2 did not block splicing (Fig.   5 ), strongly arguing that ASF/SF2 coverage of the anchoring sequence is not the mechanism by which ASF/SF2 inhibits splicing. This conclusion is further supported by the observation that moving the 3RE to position -53 (Fig. 2C) , or the MS2 operator site to position -127 (data not shown) relative to the IIIa branch site, still results in SR or MS2-ASF/SF2 protein mediated inhibition of splicing. Collectively, our data suggests a third model, namely that ASF/SF2-RBD2 functions as a specific splicing repressor domain. Potentially, ASF/SF2-RBD2 interacts directly with a component(s) required for early splice site recognition, or alternatively functions as a nucleation site for recruitment of factors that negatively affects splice site recognition. Currently we have no data that discriminate between these or other alternative mechanisms. However, our data clearly shows that ASF/SF2-RBD2 indeed functions as a splicing repressor domain when tethered to an intronic position in the IIIa or the ß-globin premRNAs. Obviously, characterization of the mechanism by which ASF/SF2-RBD2 inhibits pre-mRNA splicing is a major goal in our future research. Our initial characterization of ASF/SF2-RBD2 mutant proteins provides some interesting clues that will help in this characterization. Thus, we show that mutating the SWQDLKD motif in the putative α-helix 1 or deletion of the β4 strand of RBD2 destroys the repressor activity of ASF/SF2-RBD2, while mutations that affects the RNP1 motif or α-helix 2 has no, or minor, effect on the splicing repressor activity of RBD2. Since neither α-helix 1 nor the β4 strand is expected to be directly involved in RNA binding they may provide an essential surface for ASF/SF2-RBD2 interaction with splicing components mediating splicing repression.
In retrospect the finding that the ASF/SF2-RBD2 is sufficient for repression of IIIa splicing may provide a logical explanation to our previous observation that all tested SR proteins, except SRp20, inhibited IIIa splicing efficiently (20). Thus, SRp20, which is the shortest SR protein, encodes for only 
